{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T22:01:07Z","timestamp":1758405667946},"reference-count":23,"publisher":"American Society for Microbiology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A meningococcal group A polysaccharide (PS) conjugate vaccine (PsA-TT) has been developed for African countries affected by epidemic meningitis caused by<jats:named-content content-type=\"genus-species\">Neisseria meningitidis<\/jats:named-content>. Complement-mediated serum bactericidal antibody (SBA) assays are used to assess protective immune responses to meningococcal vaccination. Human complement (hC\u2032) was used in early studies demonstrating antibody-mediated protection against disease, but it is difficult to obtain and standardize. We developed and evaluated a method for sourcing hC\u2032 and then used the SBA assay with hC\u2032 (hSBA) to measure bactericidal responses to PsA-TT vaccination in 12- to 23-month-old African children. Sera with active complement from 100 unvaccinated blood donors were tested for intrinsic bactericidal activity, SBA titer using rabbit complement (rSBA), and anti-group A PS antibody concentration. Performance criteria and pooling strategies were examined and then verified by comparisons of three independently prepared hC\u2032 lots in two laboratories. hSBA titers of clinical trial sera were then determined using this complement sourcing method. Two different functional antibody tests were necessary for screening hC\u2032. hSBA titers determined using three independent lots of pooled hC\u2032 were within expected assay variation among lots and between laboratories. In African toddlers, PsA-TT elicited higher hSBA titers than meningococcal polysaccharide or Hib vaccines. PsA-TT immunization or PS challenge of PsA-TT-primed subjects resulted in vigorous hSBA memory responses, and titers persisted in boosted groups for over a year. Quantifying SBA using pooled hC\u2032 is feasible and showed that PsA-TT was highly immunogenic in African toddlers.<\/jats:p>","DOI":"10.1128\/cvi.00812-13","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T03:45:45Z","timestamp":1395891945000},"page":"755-761","source":"Crossref","is-referenced-by-count":16,"title":["Development and Use of a Serum Bactericidal Assay Using Pooled Human Complement To Assess Responses to a Meningococcal Group A Conjugate Vaccine in African Toddlers"],"prefix":"10.1128","volume":"21","author":[{"given":"Margaret C.","family":"Bash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freyja","family":"Lynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Mocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musa","family":"Hassan-King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Preziosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubukola","family":"Idoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samba","family":"Sow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Marc","family":"LaForce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2014,3,26]]},"reference":[{"key":"key20180919073732_B1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","author":"Lee","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073732_B2","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"Sow","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"key20180919073732_B3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"key20180919073732_B4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J. Exp. Med."},{"key":"key20180919073732_B5","doi-asserted-by":"publisher","first-page":"I40","DOI":"10.1016\/j.vaccine.2008.11.060","article-title":"Factor H and neisserial pathogenesis","volume":"26","author":"Welsch","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073732_B6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J. Exp. Med."},{"key":"key20180919073732_B7","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2002","journal-title":"Vaccine"},{"key":"key20180919073732_B8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1128\/CDLI.8.3.616-623.2001","article-title":"Importance of complement source in measuring meningococcal bactericidal titers","volume":"8","author":"Santos","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073732_B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073732_B10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol."},{"key":"key20180919073732_B11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1128\/CDLI.11.1.1-5.2004","article-title":"Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992","volume":"9","author":"Elie","year":"2002","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073732_B12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/JCM.30.1.154-159.1992","article-title":"Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay","volume":"30","author":"Carlone","year":"1992","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073732_B13","doi-asserted-by":"crossref","first-page":"A101","DOI":"10.1016\/j.vaccine.2007.04.050","article-title":"Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults","volume":"25","author":"Kshirsagar","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073732_B14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/IAI.8.6.896-900.1973","article-title":"Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A","volume":"8","author":"Myerowitz","year":"1973","journal-title":"Infect. Immun."},{"key":"key20180919073732_B15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.162.6.1837","article-title":"Escherichia coli K51 and K93 capsular polysaccharides are cross reactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies","volume":"162","author":"Guirguis","year":"1985","journal-title":"J. Exp. Med."},{"key":"key20180919073732_B16","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1016\/j.vaccine.2012.02.046","article-title":"Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations","volume":"30","author":"Khatami","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073732_B17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"key20180919073732_B18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"key20180919073732_B19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT","volume":"30","author":"Findlow","year":"2013","journal-title":"Adv. Ther."},{"key":"key20180919073732_B20","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/j.ijid.2012.10.001","article-title":"Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)","volume":"17","author":"\u00d8stergaard","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"key20180919073732_B21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/CVI.00068-09","article-title":"Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A\/C polysaccharide vaccine in adults","volume":"16","author":"Findlow","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073732_B22","first-page":"388","article-title":"Meningococcal vaccines","volume-title":"Vaccines","author":"Granoff","year":"2012","edition":"6th ed."},{"key":"key20180919073732_B23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001093.pub2","article-title":"Polysaccharide vaccines for preventing serogroup A meningococcal meningitis","author":"Patel","year":"2005","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00812-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:50:50Z","timestamp":1627591850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00812-13"}},"subtitle":[],"editor":[{"given":"C. J.","family":"Papasian","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,26]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,2]]},"published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1128\/CVI.00812-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00812-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,26]]}}}